Drug intelligence / Profile preview

ATR-01

Development stage: Preclinical
Lead developer: Azitra
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Topical

Overview

ATR-01 is a microbiome-based therapeutic developed by Azitra, a biopharmaceutical company focused on dermatology. It is an engineered *Staphylococcus epidermidis* topical live-biotherapeutic product, originating from Yale University. The drug is intended for the treatment of ichthyosis vulgaris, leveraging genetically engineered skin bacteria to address serious skin conditions.

Other names: Azitra Filaggrin Protein Therapy

Beyond the preview

Go deeper on ATR-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATR-01.

Explore the full profile